Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus

Journal of Diabetes Investigation

Volumn 2, Issue 3, 2011, Pages 204-209

  Katsuno, Tomoyuki ^a   Watanabe, Nobuaki ^b   Nagai, Etsuko ^a   Okazaki, Kazumi ^b   Yokoyama, Ariko ^b   Hamaguchi, Tomoya ^c   Miyagawa, Jun Ichiro ^a   Namba, Mitsuyoshi ^a  

^a Division of Diabetes and Metabolism   (Japan)

^b Watanabe Medical Clinic   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Glucosidase inhibitor; Glucagon like peptide 1; Mitiglinide

Indexed keywords

1,5 ANHYDROSORBITOL; ALBUMIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MITIGLINIDE; VOGLIBOSE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC DIET; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 79961055389     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00082.x     Document Type: Article

References (11)

1. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.
2. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010; 53: 450-467.
3. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
4. Després JP, Lamarche B, Mauriége P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
5. Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an α-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 active in ob/ob mice. JPET 2009; 329: 669-676.
6. Cani PD, Hoste S, Guiot Y, et al. Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br J Nutr 2007; 98: 32-37.
7. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008; 57: 678-687.
8. Gao X; Mitiglinide versus nateglinide comparison study group. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res 2009; 37: 812-821.
9. Kosaka K, Hagura R, Kuzuya T. Insulin responses in equivocal and definite diabetes, with special reference to subjects who had mild glucose intolerance but later developed definite diabetes. Diabetes 1977; 26: 944-952.
10. Mitsui R, Fukushima M, Nishi Y, et al. Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. Metabolism 2006; 55: 53-58.
11. Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984; 26: 44-49.